Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

UNC student reflects on overcoming two bouts of cancer
Days away from his 25th birthday, Derrin Mallory is set to mark another major milestone this year. 2025 marks ten years since he first heard...
Sun Jan 11, 2026

Educator, Historian and UNC Statistician Freddie Kiger Inducted Into Order of Longleaf Pine
A Chapel Hill institution and longtime community contributor was recent recognized with the highest civilian honor in North Carolina. Members of the East Chapel Hill...
Sat Jan 10, 2026

90-year-old Triad neurosurgeon ‘finally’ earns UNC undergraduate degree
Dr. David L. Kelly Jr. says this moment is a dream come true. “I’m finally getting my undergraduate degree because I lacked one course by...
Tue Jan 6, 2026

UNC School of Pharmacy retains No. 1 ranking for external research funding
The UNC Eshelman School of Pharmacy has retained its No. 1 American Association of Colleges of Pharmacy ranking for external research funding among U.S. schools...
Mon Jan 5, 2026